<DOC>
	<DOCNO>NCT00000815</DOCNO>
	<brief_summary>To compare measles seroconversion rate ( development antibody ) 13 month age HIV-infected uninfected child one two immunization schedule : attenuate measles/mumps/rubella virus ( M-M-R II ) vaccine 12 month versus attenuated measles vaccine ( Attenuvax ) 6 month plus M-M-R II vaccine 12 month . Recommendations age vaccination balance need minimize risk morbidity mortality benefit achieve high seroconversion rate . Immunizing intact immune system earlier stage HIV infection may turn achieve well long-lasting measles protection . This study help define effective measles vaccine regimen child diagnose HIV infection provide great insight functional status HIV-infected child 's humoral immune system .</brief_summary>
	<brief_title>A Phase II , Comparative Study Seroconversion Single-Dose Two-Dose Measles Vaccination HIV-Infected HIV-Uninfected Children : A Multicenter Trial Pediatric AIDS Clinical Trials Group</brief_title>
	<detailed_description>Recommendations age vaccination balance need minimize risk morbidity mortality benefit achieve high seroconversion rate . Immunizing intact immune system earlier stage HIV infection may turn achieve well long-lasting measles protection . This study help define effective measles vaccine regimen child diagnose HIV infection provide great insight functional status HIV-infected child 's humoral immune system . Patients , HIV infect uninfected , randomized one two attenuated measles vaccine schedule : 6 12 month age , 12 month age . Attenuvax administer month 6 vaccine M-M-R II month 12 vaccine . Patients follow 24 month last vaccination .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Measles</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria Patients must : Willing receive result HIV test Been bear mother HIV infection history AIDSdefining condition CDC criterion . No history opportunistic infection . No known exposure measles within 14 day prior study entry . CD4+ lymphocyte count &gt; = 750 cells/mm3 15 % 6 month age . Parent legal guardian available give write informed consent willing comply study requirement . Childhood immunization ( measles ) accord current recommendation Immunization Practice Advisory Committee American Academy Pediatrics . NOTE : Coenrollment therapeutic protocol ( except ACTG 185 ) permit . NOTE : Patients must locate geographical area measles immunization 12 month standard care . Recommended : Childhood immunization measles accord current guideline . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Intercurrent illness and/or fever 7 day . Known sensitivity allergy neomycin egg . Concurrent Medication : Excluded : IVIG . Uninterrupted anticipated steroid therapy ( &gt; = 2 mg/kg/day ) 2 week duration . Patients prior condition exclude : Platelet count &lt; 50,000/mm3 time prior study entry . Prior Medication : Excluded : Any IgG preparation within past 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>7 Months</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Measles-Mumps-Rubella Vaccine</keyword>
	<keyword>Vaccines , Attenuated</keyword>
	<keyword>Measles Vaccine</keyword>
	<keyword>Immunization Schedule</keyword>
	<keyword>Measles Virus</keyword>
	<keyword>Measles</keyword>
</DOC>